$3.30
2.08% day before yesterday
Nasdaq, Sep 19, 10:10 pm CET
ISIN
US03528H1095
Symbol
ANIX

Anixa Biosciences, Inc. Stock price

$3.30
+0.33 11.11% 1M
+0.16 5.10% 6M
+0.98 42.24% YTD
-0.12 3.51% 1Y
-2.57 43.78% 3Y
+0.84 34.15% 5Y
-1.53 31.68% 10Y
-9.70 74.62% 20Y
Nasdaq, Closing price Fri, Sep 19 2025
-0.07 2.08%
ISIN
US03528H1095
Symbol
ANIX
Industry

Key metrics

Basic
Market capitalization
$108.6m
Enterprise Value
$93.0m
Net debt
positive
Cash
$15.6m
Shares outstanding
32.2m
Valuation (TTM | estimate)
P/E
negative | negative
P/S
- | -
EV/Sales
- | -
EV/FCF
negative
P/B
6.8
Financial Health
Equity Ratio
92.6%
Return on Equity
-62.8%
ROCE
-87.1%
ROIC
-
Debt/Equity
0.0
Financials (TTM | estimate)
Revenue
$0.0 | $0.0
EBITDA
$-13.1m | -
EBIT
$-13.1m | $-14.2m
Net Income
$-12.1m | $-13.0m
Free Cash Flow
$-8.0m
Growth (TTM | estimate)
Revenue
- | -
EBITDA
- | -
EBIT
-1.4% | -2.9%
Net Income
-4.7% | -3.4%
Free Cash Flow
-11.3%
Margin (TTM | estimate)
Gross
-
EBITDA
- | -
EBIT
-
Net
- | -
Free Cash Flow
-
More
EPS
$-0.4
FCF per Share
$-0.2
Short interest
1.3%
Employees
5
Rev per Employee
$0.0
Show more

Is Anixa Biosciences, Inc. a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 7,012 stocks worldwide.

Anixa Biosciences, Inc. Stock Analysis

Unlock Scores for Free

Analyst Opinions

9 Analysts have issued a Anixa Biosciences, Inc. forecast:

8x Buy
89%
1x Hold
11%

Analyst Opinions

9 Analysts have issued a Anixa Biosciences, Inc. forecast:

Buy
89%
Hold
11%

Financial data from Anixa Biosciences, Inc.

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Apr '25
+/-
%
- -
-
100%
- Direct Costs - -
-
-
- -
-
-
- Selling and Administrative Expenses 6.87 6.87
6% 6%
-
- Research and Development Expense 6.28 6.28
10% 10%
-
-13 -13
-
-
- Depreciation and Amortization 0.06 0.06
-
-
EBIT (Operating Income) EBIT -13 -13
1% 1%
-
Net Profit -12 -12
5% 5%
-

In millions USD.

Don't miss a Thing! We will send you all news about Anixa Biosciences, Inc. directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Anixa Biosciences, Inc. Stock News

Neutral
MarketBeat
12 days ago
Investing in biotechnology stocks is typically reserved for speculative investors. For starters, many of these companies are clinical or pre-clinical stage companies.
Neutral
PRNewsWire
13 days ago
Continue to observe a positive safety profile—no dose limiting toxicities, cytokine release syndrome or immune effector cell-associated neurotoxicity SAN JOSE, Calif. , Sept. 8, 2025 /PRNewswire/ -- Anixa Biosciences, Inc. ("Anixa" or the "Company") (NASDAQ: ANIX), a biotechnology company focused on the treatment and prevention of cancer, today announced it has completed dosing of the fourth co...
Neutral
PRNewsWire
19 days ago
SAN JOSE, Calif. , Sept. 2, 2025 /PRNewswire/ -- Anixa Biosciences, Inc. ("Anixa" or the "Company") (NASDAQ: ANIX), a biotechnology company focused on the treatment and prevention of cancer, today announced that the time of management's presentation at the H.C.
More Anixa Biosciences, Inc. News

Company Profile

Anixa Biosciences, Inc. is a cancer-focused biotechnology company, which focuses on harnessing the body's immune system in the fight against cancer. It operates through the following segments: Cancer Diagnostics, Cancer Therapeutics, and Legacy Patent Licensing Activities. Cancer Diagnostic segment develops CchekTM platform, a series of inexpensive non-invasive blood tests for the early detection of solid tumors, which is based on the body's immune response to the presence of a malignancy. Cancer Therapeutics segment offers chimeric antigen receptor T-cell (CAR-T) based immuno-therapy drugs which genetically engineer a patient's own immune cells to fight cancer. The company was founded on November 5, 1982 and is headquartered San Jose, CA.

Head office United States
CEO Amit Kumar
Employees 5
Founded 1982
Website www.anixa.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today